NCT00127218View on ClinicalTrials.gov

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

PHASE3CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
AtherosclerosisCardiovascular Disease
Interventions
DRUG

any statin

Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months

DRUG

niacin

long-acting niacin daily for 18 months

DRUG

Placebo

matching placebo pill daily for 18 months

Trial Locations (1)

21218

Johns Hopkins Unversity School of Medicine, Baltimore

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Johns Hopkins University

OTHER

NCT00127218 - High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly | Biotech Hunter | Biotech Hunter